Clinical Trial Update: Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 ComboMATCH trial evaluating neratinib alone or with palbociclib for HER2-positive solid tumors, including malignant neoplasms of the female reproductive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Palbociclib (palbociclib)
• neratinib (neratinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm | Phase 2 | Status: RECRUITING